Key result
Flecainide linked to fatal interstitial lung disease unresponsive to drug discontinuation and systemic corticosteroids.
Why the study?
There is no current treatment recommendation for flecainide-induced interstitial lung disease, a rare adverse effect.
Case Report (n=1)
Flecainide can rarely induce interstitial lung disease, which may be fatal and unresponsive to drug discontinuation and systemic corticosteroids.
Answers are grounded in this paper and cite their sources.
Clinicians should monitor for ILD on flecainide; leaves open effective therapies for refractory cases.
This case describes a rare adverse effect in which the subject developed interstitial lung disease after initiating a class IC antiarrhythmic, flecainide. There is no current treatment recommendation for flecainide‐induced interstitial lung disease. Previously reported cases were successful with discontinuation of the offending drug and initiation of systemic corticosteroids; however, this patient did not respond to this treatment plan, resulting in death. Obtaining a thorough patient history regarding new medications and the start of symptoms played a crucial role when creating a differential diagnosis for this case.
No takes yet. Share an insight, caveat, or question.
Jenkins et al. (2026) conducted a case report in Flecainide-induced interstitial lung disease (n=1). Flecainide was evaluated. A patient developed fatal interstitial lung disease after initiating flecainide and did not respond to drug discontinuation and systemic corticosteroids.
Synapse has enriched 10 related papers. Consider them for comparative context: